94 search results for: Atopic Dermatitis

Watch this short video to learn how type 2 inflammation, skin barrier dysfunction, and neurosensitization contribute to chronic itch and the itch-scratch cycle in atopic dermatitis

Dr Sarina Elmariah highlights the clinical challenges in diagnosing inflammatory skin diseases, using prurigo nodularis as a case study. Drs Culton, Eichenfield, and Hawkes then join in to discuss additional challenges and complexities when diagnosing other skin diseases.

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Amy Paller, MD explores the possibilities for disease modification in atopic dermatitis.

Explore 3 interactive patient cases to learn more about the signs, symptoms, and burden of atopic dermatitis. Diagnose the patients based on a variety of cases and presentations based on American Academy of Dermatology (AAD) criteria and assess their disease severity

Join Lisa Swanson, MD, and Gina Mangin, MPAS, PA-C, for an in-depth discussion on the immunopathogenesis of atopic dermatitis (AD), highlighting the central role of key type 2 inflammatory pathways in disease development and progression. This program explores how these pathways contribute to clinical manifestations across the AD spectrum and addresses common perceptions and misconceptions surrounding AD pathomechanisms, offering clarifying insights to support informed clinical decision-making.

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Lio, MD discusses the role of atopic dermatitis as a risk factor for developing food allergies.

Join Christine Bangert and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.